Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
669actual
Sites
92
Countries
Australia, China, Hungary +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2017-01-02 | actual | When the study began enrolling |
| Primary completion | 2022-10-27 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2016-12-28 | estimated | When this record first appeared on the registry |
| Results posted | 2023-12-26 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-06-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non Small Cell Lung Carcinoma NSCLC
Interventions
- Drug: Durvalumab (MEDI4736)
- Drug: Paclitaxel + carboplatin — also filed as Platinum based Standard of Care Chemotherapy
- Drug: Gemcitabine + cisplatin — also filed as Platinum based Standard of Care Chemotherapy
- Drug: Gemcitabine + carboplatin — also filed as Platinum based Standard of Care Chemotherapy
- Drug: Pemetrexed + cisplatin — also filed as Platinum based Standard of Care Chemotherapy
- Drug: Pemetrexed + carboplatin — also filed as Platinum based Standard of Care Chemotherapy
Primary outcomes
what the primary-completion date above is the date OFOverall Survival (OS)
measured From date of randomization until death due to any cause. Assessed up to a maximum of approximately 69 months [data cut-off (DCO) 27 October 2022]
OS in Participants With LREM
measured From date of randomization until death due to any cause. Assessed up to a maximum of approximately 69 months (DCO 27 October 2022)
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2021-06-18 · 4.3 MB · Prot_000.pdf
Statistical Analysis Planposted 2021-06-11 · 2.6 MB · SAP_001.pdf
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed